Riluzole → HCID 58397608, compound
Reaction equation
[CH3:1][S:2]([C:5]1[CH:6]=[C:7]([NH2:13])[C:8]([NH:11][CH3:12])=[CH:9][CH:10]=1)(=[O:4])=[O:3].[NH2:14][C:15]1[S:16][C:17]2[CH:23]=[C:22]([O:24][C:25]([F:28])([F:27])[F:26])[CH:21]=[CH:20][C:18]=2[N:19]=1.[C:29](N1C=CN=C1)(N1C=CN=C1)=S>C(Cl)CCl>[CH3:1][S:2]([C:5]1[CH:10]=[CH:9][C:8]2[N:11]([CH3:29])[C:12]([NH:14][C:15]3[S:16][C:17]4[CH:23]=[C:22]([O:24][C:25]([F:28])([F:26])[F:27])[CH:21]=[CH:20][C:18]=4[N:19]=3)=[N:13][C:7]=2[CH:6]=1)(=[O:3])=[O:4]Participants
5
Reactant 3
Product 1
Reagents, catalysts & solvents 1
Procedure
(5-Methanesulfonyl-1-methyl-1H-benzoimidazol-2-yl)-(6-trifluoromethoxy-benzothiazol-2-yl)-amine (72 mg) was prepared by following General Procedure D starting from 4-methanesulfonyl-N1-methyl-benzene-1,2-diamine (50 mg), 2-amino-6-(trifluoromethoxy)benzothiazole (59 mg), 1,1′-thiocarbonyl-diimidazole (44 mg), and EDC (48 mg). LC/MS: m/z 444.
Sources & evidence
- ORD record
- ord-09d491e28bec4f12b489aa7fe19c87cf
- Source dataset
- uspto-grants-2014_06
- Patent number
- US08759535B2
Reaction notes
Loading…